Supartz (also known as Supartz FX in the US) is a hyaluronic acid viscosupplement used for the symptomatic treatment of knee osteoarthritis pain. Manufactured by Bioventus, Supartz FX is administered as a course of five weekly intra-articular injections. It has an extensive clinical track record and remains a widely used viscosupplementation option in orthopaedic and sports medicine practice. This guide covers everything practitioners need to know about Supartz — from its formulation and mechanism of action to injection technique, dosing schedule, side effects, and how it compares to other viscosupplements.

What Is Supartz FX?

Supartz FX is a sterile, non-pyrogenic solution of highly purified sodium hyaluronate derived from rooster combs (avian source). It is supplied as a prefilled syringe containing 2.5 ml of sodium hyaluronate at a concentration of 10 mg/ml (25 mg per syringe).

Key product specifications:

  • HA concentration: 10 mg/ml
  • Volume per injection: 2.5 ml (25 mg per syringe)
  • Injections per course: 5 weekly injections
  • Molecular weight: 620,000–1,170,000 Daltons
  • Origin: Avian (rooster comb derived)
  • Regulatory status: FDA-cleared (US)

Supartz’s avian origin is a key clinical consideration. Patients with known bird or egg allergies should not receive Supartz — for these patients, non-animal-sourced alternatives such as Orthovisc, Monovisc, or Durolane are preferred.

Licensed practitioners can order Supartz FX at wholesale prices through Bioresus.

How Does Supartz Work?

In osteoarthritis, the concentration and molecular weight of native HA in synovial fluid decreases, reducing its protective properties and increasing friction, pain, and joint damage. Supartz works by restoring the viscoelastic and lubricating properties of synovial fluid. Injected into the knee joint, it:

  • Supplements depleted native hyaluronic acid in the joint space
  • Reduces friction between articular cartilage surfaces during movement
  • Absorbs mechanical shock during weight-bearing activities
  • May exert anti-inflammatory effects via interaction with surface receptors on synoviocytes
  • May stimulate endogenous HA production by synoviocytes over time

The therapeutic benefit of Supartz typically extends well beyond its residence time in the joint, suggesting biological effects — rather than pure mechanical lubrication — contribute to the sustained pain relief observed in clinical trials.

Indications for Supartz Injection

  • Adults with Kellgren-Lawrence Grade I–III knee osteoarthritis
  • Patients who have not responded adequately to physiotherapy, weight management, and analgesics
  • Patients seeking a non-surgical, non-opioid pain management option
  • Active patients, athletes, or those with occupational demands who need to maintain function
  • Patients who wish to delay or avoid total knee replacement surgery
  • No bird or egg allergy (avian origin — allergy screening mandatory before prescribing)

Contraindications

  • Known hypersensitivity to hyaluronic acid or any component of the formulation
  • Known allergy to avian proteins, feathers, or egg products — Supartz is derived from rooster combs and is contraindicated in these patients
  • Active infection or skin disease at or near the injection site
  • Active intra-articular infection or joint inflammation
  • Venous or lymphatic stasis in the affected limb
  • Pregnancy or breastfeeding (insufficient safety data)

The avian origin of Supartz is the most clinically significant contraindication consideration. Screen specifically for bird and egg allergy before prescribing. For patients with such allergies, non-animal-sourced viscosupplements are the appropriate alternatives.

Supartz Dosage and Treatment Schedule

Standard Protocol

  • Five weekly intra-articular injections of 2.5 ml (25 mg sodium hyaluronate) into the affected knee
  • Injections administered at weekly intervals (7-day spacing recommended)
  • Re-treatment may be considered 6 months after the initial course, based on clinical response

The five-injection protocol is longer than single-injection (Durolane, Monovisc) and three-injection (Orthovisc) alternatives. For practices where patient compliance with multiple visits is a concern, a shorter-protocol product may be more appropriate.

Re-Treatment

Document baseline and follow-up pain scores (VAS or NRS) and functional assessments (WOMAC, KOOS) to support evidence-based retreatment decisions. Most responding patients can be retreated at 6-month intervals.

Supartz Injection Technique

Equipment Required

  • Supartz FX 2.5 ml prefilled syringe
  • 21–23 gauge needle (not supplied — attach at time of administration)
  • Sterile gloves and draping
  • Antiseptic skin preparation solution
  • Optional: local anaesthetic (lidocaine 1%) — Supartz FX does not contain integrated lidocaine

Injection Approaches

Superolateral approach (most common):

  • Patient supine with knee fully extended
  • Insert needle superior and lateral to the patella, directing medially and slightly inferiorly
  • Aspirate any significant joint effusion before injecting Supartz; inject 2.5 ml slowly with minimal resistance

Anteromedial or anterolateral approach (knee flexed at 90°):

  • Patient seated with knee at 90°; insert needle adjacent to the patellar tendon, medially or laterally
  • Suitable for patients who cannot achieve full knee extension

Ultrasound guidance is strongly recommended for all intra-articular knee injections, consistently demonstrating higher placement accuracy compared to landmark-guided techniques — particularly in patients with obesity or significant anatomical changes.

Post-Injection Patient Instructions

  • Avoid strenuous activity, prolonged standing, and heavy lifting for 48 hours post-injection
  • Ice application to the knee for 15–20 minutes may reduce discomfort
  • Mild swelling, warmth, or stiffness for 24–72 hours is expected and self-limiting
  • Meaningful pain relief typically takes 4–8 weeks to onset — advise patients not to assess efficacy before this period
  • Ensure patients understand they need to return for all five injections to complete the course

Supartz Side Effects and Safety Profile

Common (Local, Transient)

  • Injection site pain — most frequently reported, typically mild and short-lived
  • Swelling or effusion — usually resolves within 48–72 hours
  • Warmth or redness around the knee
  • Stiffness post-injection

Serious (Rare)

  • Septic arthritis — minimised with strict aseptic technique; urgent evaluation if fever or rapidly worsening symptoms develop
  • Acute inflammatory (pseudoseptic) reaction — sudden increase in pain and swelling within 24–72 hours; usually self-limiting
  • Hypersensitivity or allergic reactions — more likely with avian-sourced HA in sensitised patients; practitioners should be equipped to manage anaphylaxis

The avian origin of Supartz means the risk of allergic reaction is higher than for non-animal-sourced products. Pre-treatment allergy screening is essential.

Expected Clinical Outcomes

  • Significant reductions in pain VAS scores versus placebo at 5 and 13 weeks post-treatment
  • Meaningful improvements in WOMAC pain, stiffness, and physical function subscale scores
  • Clinical response sustained for up to 6 months in responding patients
  • Responder rates of approximately 60–70% in patients with mild-to-moderate OA

As with all viscosupplementation products, outcomes are best in patients with Kellgren-Lawrence Grade II–III OA. Grade IV patients are unlikely to benefit meaningfully.

Supartz vs Other Viscosupplements

  • Supartz vs Durolane: Durolane is a single-injection, non-animal-sourced product. Supartz requires five injections and carries avian allergy risk. Durolane is significantly more convenient.
  • Supartz vs Monovisc: Monovisc is a single-injection, non-animal-sourced alternative offering far greater scheduling convenience.
  • Supartz vs Orthovisc: Both are multi-injection regimens. Orthovisc requires 3–4 injections vs Supartz’s 5, and uses non-animal-sourced HA. Orthovisc is generally preferable if a multi-injection protocol is indicated.
  • Supartz vs Synvisc: Both are avian-derived and multi-injection. Synvisc uses hylan GF-20 (cross-linked HA derivative); Supartz uses native sodium hyaluronate.
  • Supartz vs Euflexxa: Euflexxa is a 3-injection, non-animal-sourced alternative. Euflexxa’s shorter protocol and non-avian origin make it preferable in most settings.

Patient Selection and Counselling

Ideal candidates:

  • Kellgren-Lawrence Grade II–III knee OA, no bird or egg allergy
  • Adequate compliance with a 5-week treatment schedule
  • Non-response to conservative management after adequate trial

Key counselling points:

  • Five clinic visits over five weeks are required — patient commitment to the full schedule is important
  • Supartz provides symptomatic relief only, not disease modification
  • Pain relief takes 4–8 weeks to onset after the final injection
  • Avian allergy screening is mandatory before treatment
  • Non-response is possible; approximately 30–40% of patients do not achieve meaningful relief

Ordering Supartz FX Wholesale

Licensed practitioners can order Supartz FX at wholesale prices from Bioresus. Browse the full orthopaedic injectable range including Supartz FX, Durolane, Orthovisc, and Monovisc. All products are sourced from authorised distributors.

Conclusion

Supartz FX has a long clinical track record in viscosupplementation and remains a viable option for knee osteoarthritis management — particularly in practices with an established protocol for its 5-injection course. However, its avian origin and longer injection schedule mean practitioners should carefully weigh it against non-animal-sourced, shorter-protocol alternatives such as Durolane and Monovisc for most patients.